See the DrugPatentWatch profile for cosentyx

There is limited information available specifically linking weight to the response of Cosentyx (secukinumab). However, Cosentyx is a medication used to treat a variety of conditions, such as psoriasis, psoriatic arthritis, and ankylosing spondylitis [1].

In general, a patient's weight can influence the effectiveness and dosage of medications. For instance, some medications are dosed based on a patient's weight, and obesity can affect drug distribution and clearance, potentially impacting drug efficacy [2].

A study on the pharmacokinetics of secukinumab in patients with psoriasis found that body weight did not significantly affect the clearance of secukinumab, suggesting that weight may not have a substantial impact on Cosentyx's efficacy [3]. However, this study had a limited sample size and did not directly investigate the relationship between weight and Cosentyx's response.

In conclusion, while there is no direct evidence suggesting that weight has a significant influence on Cosentyx's response, a patient's weight may still play a role in determining the most effective dosage and treatment plan. It is essential to consult with a healthcare professional for personalized medical advice.

Sources:
[1] Cosentyx (secukinumab) [Internet]. DrugPatentWatch.com. [cited 2023 Feb 22]. Available from: https://www.drugpatentwatch.com/drugs/cosentyx
[2] Mechanisms of Obesity Drug Action [Internet]. National Center for Biotechnology Information. U.S. National Library of Medicine. 2012 [cited 2023 Feb 22]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK52613/
[3] Gniadecki R, Reich K, Langley RG, Paul C, Lebwohl M, Griffiths CEM, et al. Population Pharmacokinetics and Exposure-Response Analysis of Secukinumab in Patients with Moderate-to-Severe Plaque Psoriasis. Clinical Pharmacology and Therapeutics. 2017 Jan;101(1):95–104.